Comparative Pharmacology
Head-to-head clinical analysis: CYCLAINE versus HEAVY SOLUTION NUPERCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAINE versus HEAVY SOLUTION NUPERCAINE.
CYCLAINE vs HEAVY SOLUTION NUPERCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclaine is a local anesthetic that reversibly blocks nerve conduction by decreasing the permeability of the neuronal membrane to sodium ions, thereby stabilizing the membrane and preventing the initiation and transmission of electrical impulses.
Heavy solution nupercaine (dibucaine) is a potent, long-acting amide local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the propagation of action potentials and preventing nerve impulse conduction.
0.2–0.4 mg/kg IV for induction; 0.5–1.5 mg/kg/h IV infusion for maintenance.
Spinal anesthesia: 0.5-1 mL of 0.5% heavy solution (2.5-5 mg) injected intrathecally; dose depends on level of anesthesia required.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged with hepatic impairment.
Terminal elimination half-life is 2.5-4 hours (mean 3.5 h) in adults. In neonates, half-life is prolonged (up to 8-12 h) due to immature hepatic function.
Renal: minimal (<5% unchanged); biliary/fecal: >70% as metabolites; small amount exhaled as CO2.
Primarily hepatic metabolism to inactive metabolites; renal excretion of unchanged drug accounts for approximately 1-5%. Biliary excretion is minimal (<5%). Total fecal elimination is negligible (<1%).
Category C
Category C
Local Anesthetic
Local Anesthetic